Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-338.79	-83.82	-65.8	-80.89	-78.25
Depreciation & Amortization	0.96	1.96	2	1.62	0.9
Share-Based Compensation	25.68	7.11	8.04	6.26	4.88
Other Operating Activities	212.24	-5.4	2.05	-2.76	6.79
Operating Cash Flow	-99.91	-80.14	-53.72	-75.78	-65.69
Capital Expenditures	0.48	-0.04	-0.57	-4.28	-1.49
Acquisitions	18.04	0	0	0	0
Change in Investments	-126.9	57.05	-22.05	-3.32	-0.25
Investing Cash Flow	-108.39	57.01	-22.62	-7.6	-1.74
Share Issuance / Repurchase	84.96	43.1	1.9	154.53	65.75
Debt Issued / Paid	-0.02	-0.42	-0.51	-0.02	-0.03
Other Financing Activities	276.13	-	-	-	-
Financing Cash Flow	361.08	42.68	1.39	154.51	65.72
Exchange Rate Effect	0.03	-0.11	-0.02	0.05	0
Net Cash Flow	152.8	19.44	-74.96	71.18	-1.71
Free Cash Flow	-99.44	-80.18	-54.29	-80.06	-67.18
Free Cash Flow Margin	-11222.91%	-3442.77%	-289.71%	-	-
Free Cash Flow Per Share	-14.42	-23.78	-20.64	-37.50	-52.57

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).